Merck announced that sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago. The pharma giant also narrowed its full-year profit outlook ...
Stocktwits on MSN
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
VKTX shares have surged about 45% in October, set for their strongest monthly gain of 2025. ・Traders on Stocktwits linked ...
I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to ...
Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...
Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...
The drugmaker issued the recall voluntarily after determining higher-than-acceptable levels may be present in some products.
Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...
US President Trump wraps up his Asia tour with major trade and security announcements, while Israel’s Netanyahu issues a ...
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback